Mostrar o rexistro simple do ítem
dc.contributor.author | Gutiérrez Lovera, Carlha Rodmar |
dc.contributor.author | Vázquez Ríos, Abi Judit |
dc.contributor.author | Guerra Varela, Jorge |
dc.contributor.author | Sánchez Piñón, Laura Elena |
dc.contributor.author | Fuente Freire, María de la |
dc.date.accessioned | 2021-05-04T12:30:45Z |
dc.date.available | 2021-05-04T12:30:45Z |
dc.date.issued | 2017 |
dc.identifier.citation | Genes 2017, 8(12), 349; https://doi.org/10.3390/genes8120349 |
dc.identifier.uri | http://hdl.handle.net/10347/26107 |
dc.description.abstract | In the last few decades, the field of nanomedicine applied to cancer has revolutionized cancer treatment: several nanoformulations have already reached the market and are routinely being used in the clinical practice. In the case of genetic nanomedicines, i.e., designed to deliver gene therapies to cancer cells for therapeutic purposes, advances have been less impressive. This is because of the many barriers that limit the access of the therapeutic nucleic acids to their target site, and the lack of models that would allow for an improvement in the understanding of how nanocarriers can be tailored to overcome them. Zebrafish has important advantages as a model species for the study of anticancer therapies, and have a lot to offer regarding the rational development of efficient delivery of genetic nanomedicines, and hence increasing the chances of their successful translation. This review aims to provide an overview of the recent advances in the development of genetic anticancer nanomedicines, and of the zebrafish models that stand as promising tools to shed light on their mechanisms of action and overall potential in oncology |
dc.description.sponsorship | This work was supported by the Xunta de Galicia, Spain (Competitive Reference Groups, GRC2014/010), the Carlos III Health Institute/FEDER (PI15/00828), and the Spanish Ministry of Education, Culture and Sport (FPU15/06595) |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.rights | © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/) |
dc.rights | Atribución 4.0 Internacional |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.subject | Nanomedicines |
dc.subject | Cancer |
dc.subject | Gene therapies |
dc.subject | Zebrafish |
dc.subject | Translation |
dc.title | The Potential of Zebrafish as a Model Organism for Improving the Translation of Genetic Anticancer Nanomedicines |
dc.type | journal article |
dc.identifier.doi | 10.3390/genes8120349 |
dc.relation.publisherversion | https://doi.org/10.3390/genes8120349 |
dc.type.hasVersion | VoR |
dc.identifier.essn | 2073-4425 |
dc.rights.accessRights | open access |
dc.contributor.affiliation | Universidade de Santiago de Compostela. Departamento de Zooloxía, Xenética e Antropoloxía Física |
dc.description.peerreviewed | SI |
Ficheiros no ítem
Este ítem aparece na(s) seguinte(s) colección(s)
-
ZAF-Artigos [273]